PRAXBIND is indicated in patients treated with Pradaxa® when reversal of the anticoagulant effects of dabigatran is needed:
This indication is approved under accelerated approval based on a reduction in unbound dabigatran and normalization of coagulation parameters in healthy volunteers. Continued approval for this indication may be contingent upon the results of an ongoing cohort case series study.
Please click here for full Prescribing Information for PRAXBIND.
Boehringer Ingelheim Pharmaceuticals, Inc. either owns or uses the trademarks Praxbind®, PRAXBIND with associated design ®, Pradaxa®, and RE-VERSE AD™ under license.
Use of this Site is subject to the Internet Site Legal Notices and Disclaimers and Privacy Notice. This Site is intended for U.S. healthcare professionals only.
Products discussed herein may have different labeling in different countries.
Copyright © 2016 Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved. [08/16]
This website is intended for U.S. healthcare professionals only.
Please choose an option below: